Drugs for Gastrointestinal Diseases

On this page

🎯 Gastrointestinal Pharmacology Mastery: Your Clinical Arsenal

Gastrointestinal pharmacology transforms abstract physiology into precise clinical action-you'll master how proton pump inhibitors silence acid secretion, how prokinetics orchestrate motility, and how biologics rewire inflammatory cascades in IBD. This lesson builds your therapeutic decision-making from mechanism to bedside, integrating when to suppress, when to stimulate, and when to modulate immune responses across the entire digestive tract. You'll emerge with a systematic framework for matching drug classes to pathophysiology, anticipating adverse effects, and navigating complex multi-system scenarios where GI therapy intersects cardiology, nephrology, and beyond.

📌 Remember: GASTRO - Gastric acid suppressors, Antiemetics, Stimulant laxatives, Tidine H2 blockers, Receptor modulators, Osmotic agents - covers the six major GI drug categories with 85% clinical coverage

The therapeutic landscape spans from simple antacids providing 30-60 minute symptomatic relief to complex biologic agents requiring 12-16 week induction protocols. Understanding this pharmacological spectrum enables precise therapeutic selection based on disease severity, patient factors, and treatment goals.

⭐ Clinical Pearl: 95% of peptic ulcer disease responds to appropriate acid suppression therapy, but only 60% achieve optimal outcomes without proper drug selection and dosing protocols

Drug ClassOnset TimeDurationPrimary MechanismClinical Success Rate
Antacids2-5 minutes30-60 minutesDirect neutralization85% symptomatic
H2 Antagonists30-60 minutes6-12 hoursReceptor blockade70% healing
PPIs1-3 days24+ hoursEnzyme inhibition90% healing
Prokinetics15-30 minutes4-6 hoursMotility enhancement75% improvement
Biologics2-8 weeks8-12 weeksImmune modulation65% remission

The 12+ billion dollar global GI therapeutics market reflects the clinical importance of these medications, with proton pump inhibitors accounting for 35% of prescriptions and biologic therapies representing the fastest-growing segment at 15% annual growth. Understanding this therapeutic arsenal transforms clinical decision-making from empirical treatment to precision medicine approaches.

🎯 Gastrointestinal Pharmacology Mastery: Your Clinical Arsenal

🔬 Acid Suppression Mastery: The Gastric Control Center

Loading diagram…

📌 Remember: PUMP - Parietal cell targets, Unidirectional inhibition, Millimolar concentrations, PH restoration - describes proton pump inhibitor mechanisms achieving 90%+ acid suppression

  • Proton Pump Inhibitors (PPIs)

    • Irreversible enzyme inhibition lasting 24-72 hours
    • Require acid activation for therapeutic effect
    • Achieve 90-95% acid suppression at therapeutic doses
      • Omeprazole: 20-40 mg daily, CYP2C19 metabolism
      • Esomeprazole: 20-40 mg daily, improved bioavailability
      • Pantoprazole: 40-80 mg daily, minimal drug interactions
  • H2 Receptor Antagonists

    • Competitive histamine receptor blockade
    • 70-80% acid suppression, 6-12 hour duration
    • Rapid tolerance development within 2-4 weeks
      • Ranitidine: 150-300 mg twice daily
      • Famotidine: 20-40 mg twice daily
      • Cimetidine: 400-800 mg twice daily, significant interactions

⭐ Clinical Pearl: Nocturnal acid breakthrough occurs in 70% of PPI users, requiring H2 antagonist addition for 24-hour acid control in refractory cases

ParameterPPIsH2 AntagonistsAntacids
Onset1-3 days30-60 min2-5 min
Peak Effect5-7 days1-2 hours15-30 min
Acid Suppression90-95%70-80%Variable
Duration24+ hours6-12 hours30-60 min
ToleranceMinimalSignificantNone

The step-down therapy approach utilizes initial PPI treatment achieving 85% ulcer healing at 4 weeks, followed by H2 antagonist maintenance reducing recurrence rates to <15% annually. This strategy balances therapeutic efficacy with cost-effectiveness and long-term safety considerations.

🔬 Acid Suppression Mastery: The Gastric Control Center

🎛️ Motility Modulation Arsenal: The Peristaltic Command System

  • Dopamine D2 Antagonists
    • Central and peripheral dopamine receptor blockade
    • Metoclopramide: 10-20 mg three times daily
      • Gastric emptying acceleration by 25-40%
      • Antiemetic effect through CTZ blockade
      • Extrapyramidal side effects in 15-20% of patients
    • Domperidone: 10-20 mg three times daily
      • Peripheral D2 selectivity, minimal CNS penetration
      • Cardiac QT prolongation risk at doses >30 mg daily

📌 Remember: MOVE - Metoclopramide central action, Outside brain domperidone, Vagal stimulation, Emptying acceleration - distinguishes prokinetic mechanisms with 80%+ efficacy in gastroparesis

Loading diagram…
  • 5-HT4 Receptor Agonists

    • Cisapride: Withdrawn due to cardiac arrhythmias
    • Prucalopride: 2 mg daily for chronic constipation
      • Selective 5-HT4 agonism without cardiac toxicity
      • Colonic transit acceleration by 40-60%
      • Complete spontaneous bowel movements increase by 1.5-2.5 weekly
  • Motilin Receptor Agonists

    • Erythromycin: 250-500 mg three times daily
      • Motilin receptor activation at sub-antimicrobial doses
      • Gastric emptying improvement within 30-60 minutes
      • Tachyphylaxis development limits long-term use

⭐ Clinical Pearl: Gastroparesis management requires combination therapy in 60% of cases, with dietary modification plus prokinetic agents achieving 75% symptom improvement versus 45% with monotherapy

Drug ClassPrimary TargetOnset TimeEfficacy RateMajor Limitation
D2 AntagonistsCNS/Peripheral30-60 min70-80%Extrapyramidal effects
5-HT4 AgonistsEnteric neurons1-2 hours65-75%Cardiac concerns
Motilin AgonistsSmooth muscle15-30 min80-90%Tachyphylaxis
Cholinesterase InhibitorsAcetylcholine45-90 min60-70%Cholinergic toxicity

The treatment algorithm prioritizes dietary modifications achieving 30% improvement, followed by single-agent prokinetics providing additional 40% benefit, with combination therapy reserved for refractory cases requiring specialized gastroenterology management.

🎛️ Motility Modulation Arsenal: The Peristaltic Command System

🎯 Anti-Inflammatory Precision: The IBD Treatment Matrix

  • Aminosalicylates (5-ASA)
    • Topical anti-inflammatory action in colonic mucosa
    • Sulfasalazine: 2-4 grams daily divided doses
      • Sulfapyridine carrier delivers 5-ASA to colon
      • Folate deficiency risk requires supplementation
      • Male infertility reversible with discontinuation
    • Mesalamine: 2.4-4.8 grams daily
      • pH-dependent or time-release formulations
      • Maintenance remission in 70-80% of UC patients
      • Nephrotoxicity monitoring requires annual creatinine

📌 Remember: SALAD - Sulfasalazine splits, Aminosalic acid active, Local action, Anti-inflammatory, Dose-dependent - describes 5-ASA mechanisms achieving 75% mild-moderate UC response

Loading diagram…
  • Corticosteroids

    • Broad anti-inflammatory effects with rapid onset
    • Prednisolone: 40-60 mg daily for acute flares
      • Remission induction in 80-90% within 2-4 weeks
      • Taper schedule over 8-12 weeks prevents rebound
      • Long-term complications limit use to <3 months annually
    • Budesonide: 9 mg daily for ileal/right-sided disease
      • High first-pass metabolism reduces systemic exposure
      • Equivalent efficacy with reduced side effects
  • Biologic Therapies

    • TNF-α Inhibitors: Infliximab, Adalimumab, Certolizumab
      • Induction protocols require weeks 0, 2, 6 dosing
      • Remission rates: 60-65% at week 10-12
      • Infection screening mandatory before initiation
    • Integrin Antagonists: Vedolizumab 300 mg IV
      • Gut-selective α4β7 integrin blockade
      • Lower infection risk than systemic immunosuppression
      • Slower onset requiring 12-14 weeks for full effect

⭐ Clinical Pearl: Combination therapy with immunomodulators plus biologics achieves 75% remission rates versus 55% with biologic monotherapy, but increases infection risk by 2.5-fold

Treatment CategoryInduction SuccessMaintenance EfficacyTime to ResponseMajor Risks
5-ASA60-70%70-80%2-4 weeksNephrotoxicity
Corticosteroids80-90%Not suitable1-2 weeksMultiple systemic
TNF Inhibitors60-65%50-60%6-12 weeksSerious infections
Vedolizumab45-50%40-45%12-14 weeksMinimal
JAK Inhibitors55-60%45-50%8-10 weeksThrombosis risk

The step-up versus top-down debate favors early aggressive therapy in high-risk patients with extensive disease, deep ulcerations, or extraintestinal manifestations, achieving better long-term outcomes despite higher initial costs and adverse effect risks.

🎯 Anti-Inflammatory Precision: The IBD Treatment Matrix

⚖️ Therapeutic Decision Architecture: The Clinical Algorithm Matrix

  • Peptic Ulcer Disease Algorithm
    • H. pylori testing mandatory in all patients
    • Triple therapy: PPI + Amoxicillin + Clarithromycin × 14 days
      • Eradication rates: 85-90% with first-line therapy
      • Bismuth quadruple therapy for penicillin allergy
      • Post-treatment testing at 4-6 weeks after completion
    • NSAID-induced ulcers: PPI therapy × 8-12 weeks
      • Misoprostol co-therapy for high-risk patients
      • COX-2 selective inhibitors reduce GI toxicity by 50%
Loading diagram…

📌 Remember: TREAT - Test for H. pylori, Remove NSAIDs, Eradicate bacteria, Acid suppression, Test cure - covers 95% of peptic ulcer management with 90%+ success rates

  • GERD Management Stratification

    • Lifestyle modifications: Weight loss, head elevation, dietary changes
      • Symptom improvement in 40-50% of mild cases
      • BMI reduction of 5-10% provides significant benefit
    • Step-up therapy: H2 antagonists → PPIs → high-dose PPIs
      • Symptom resolution in 85% with standard PPI dosing
      • Refractory cases may require twice-daily dosing
    • Surgical intervention: Nissen fundoplication for medical failures
      • Long-term success in 90% of appropriately selected patients
  • Constipation Treatment Hierarchy

    • Bulk-forming agents: Psyllium 3.4 grams twice daily
      • Gradual onset over 2-3 days
      • Adequate fluid intake essential to prevent obstruction
    • Osmotic laxatives: Polyethylene glycol 17 grams daily
      • Dose titration based on stool frequency and consistency
      • Electrolyte monitoring in elderly or renal impairment
    • Stimulant laxatives: Senna 8.6-17.2 mg at bedtime
      • Reserved for refractory cases due to dependency risk
      • Short-term use recommended <1 week

⭐ Clinical Pearl: Combination therapy achieves superior outcomes in refractory cases-PPI + H2 antagonist for nocturnal GERD, 5-ASA + immunomodulator for IBD maintenance, osmotic + stimulant for severe constipation

Clinical ScenarioFirst-Line TherapySuccess RateSecond-Line OptionsSpecialist Referral
H. pylori (+) PUDTriple therapy85-90%Bismuth quadrupleResistance testing
GERD symptomsPPI 4-8 weeks80-85%High-dose PPIpH monitoring
Functional constipationFiber + fluids60-70%Osmotic laxativesMotility studies
UC flare5-ASA therapy70-75%CorticosteroidsBiologic therapy
GastroparesisDietary + prokinetic65-70%Combination drugsGastric stimulator

The treat-to-target approach emphasizes objective endpoints over symptomatic improvement alone-endoscopic healing in IBD, pH normalization in GERD, and H. pylori eradication in peptic ulcer disease predict long-term success and reduced complications.

⚖️ Therapeutic Decision Architecture: The Clinical Algorithm Matrix

🔗 Advanced Integration Nexus: The Multi-System Therapeutic Web

  • CYP450 Enzyme Interactions
    • Omeprazole: CYP2C19 inhibitor affecting clopidogrel activation
      • Reduced antiplatelet efficacy by 25-30%
      • Alternative PPIs (pantoprazole) show minimal interaction
      • Genetic polymorphisms affect metabolism in 15-20% of patients
    • Cimetidine: Multiple CYP inhibition causing drug accumulation
      • Warfarin levels increase by 15-25%
      • Theophylline clearance reduced by 30-40%
      • Phenytoin toxicity risk with concurrent use

📌 Remember: CYPHER - Cimetidine inhibits, Yield drug levels, Pantoprazole preferred, Hepatic metabolism, Enzyme competition, Reduced clearance - describes CYP450 interactions affecting 60% of co-administered drugs

Loading diagram…
  • Cardiovascular System Integration

    • Domperidone: QT prolongation risk at >30 mg daily
      • Contraindicated with cardiac arrhythmias
      • Drug interactions with CYP3A4 inhibitors
      • ECG monitoring recommended in high-risk patients
    • 5-ASA compounds: Myocarditis and pericarditis risk
      • Incidence: 1 in 1000-10,000 patients
      • Onset: 2-4 weeks after initiation
      • Reversible with prompt discontinuation
  • Renal System Considerations

    • Mesalamine: Interstitial nephritis in <1% of patients
      • Annual creatinine monitoring recommended
      • Dose reduction required with CrCl <50 mL/min
      • Contraindicated with severe renal impairment
    • PPIs: Chronic kidney disease association
      • Long-term use (>1 year) increases CKD risk by 20-50%
      • Acute interstitial nephritis rare but serious complication
      • Magnesium depletion with prolonged therapy

⭐ Clinical Pearl: Polypharmacy management requires systematic interaction screening-drug interaction checkers identify clinically significant interactions in 85% of complex regimens, preventing adverse events in 15-20% of cases

System InteractionDrug ExamplesClinical ConsequenceMonitoring RequiredRisk Mitigation
Hepatic CYP450Omeprazole + ClopidogrelReduced antiplatelet effectPlatelet functionAlternative PPI
Cardiac QTDomperidone + AzithromycinArrhythmia riskECG monitoringDose reduction
Renal FunctionMesalamine + NSAIDsNephrotoxicityCreatinine levelsNSAID avoidance
ElectrolytePPI + DiureticsHypomagnesemiaMagnesium levelsSupplementation
AbsorptionPPI + Iron/B12Deficiency statesNutritional markersReplacement therapy

The precision medicine approach incorporates genetic testing for CYP2C19 polymorphisms affecting PPI metabolism, TPMT activity influencing azathioprine dosing, and pharmacokinetic modeling for biologic therapy optimization in complex IBD management.

🔗 Advanced Integration Nexus: The Multi-System Therapeutic Web

🎯 Clinical Mastery Toolkit: The Rapid-Fire Reference Arsenal

📌 Remember: DIGEST - Dosing precision, Interaction awareness, Guideline adherence, Emergency protocols, Safety monitoring, Timing optimization - encompasses 90% of clinical GI pharmacology decisions

  • Emergency Drug Protocols

    • Acute GI bleeding: PPI 80 mg IV bolus + 8 mg/hour infusion
      • Hemodynamic stabilization takes priority
      • Endoscopy within 24 hours for high-risk patients
      • Transfusion threshold: Hemoglobin <7 g/dL
    • Severe IBD flare: Methylprednisolone 1 mg/kg IV daily
      • Maximum 60-80 mg daily
      • Infection screening before initiation
      • Surgical consultation if no improvement in 72 hours
  • Critical Monitoring Parameters

    • Biologic therapy: CBC, LFTs every 3 months
    • Azathioprine: TPMT testing before initiation
    • Long-term PPIs: B12, magnesium annually
    • Mesalamine: Creatinine every 6-12 months

⭐ Clinical Pearl: Drug-specific monitoring prevents 90% of serious adverse events-systematic protocols reduce medication errors by 75% and improve patient outcomes through early detection of complications

Clinical ScenarioImmediate ActionDosing ProtocolMonitoringDuration
Acute PUD bleedingIV PPI bolus80 mg + 8 mg/hrHemoglobin q6h72 hours
Severe UC flareIV steroids1 mg/kg dailyDaily assessment5-7 days
C. diff colitisOral vancomycin125 mg QIDStool toxin10-14 days
Gastroparesis crisisIV metoclopramide10 mg q6hNeurologic exam48-72 hours
HyperemesisOndansetron4-8 mg q8hElectrolytesUntil resolution

The mastery framework emphasizes pattern recognition, systematic thinking, and evidence-based decision-making as core competencies for clinical success and examination performance in competitive medical environments.

🎯 Clinical Mastery Toolkit: The Rapid-Fire Reference Arsenal

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

All Lessons (10)

Practice Questions: Drugs for Gastrointestinal Diseases

  1. 1. Which of the following is NOT an H2 receptor antagonist?

    • A. Rantac
    • B. Nexium
    • C. Tagamet
    • D. Famocid
    Show answer

    Answer: B. Nexium

    > Key point: Nexium (esomeprazole) is a proton pump inhibitor, not an H2 receptor antagonist. Why Nexium is correct - Esomeprazole suppresses acid secretion by inhibiting the gastric proton pump rather than blocking H2 receptors. How they compare | Drug | Class | |---|---| | Nexium | Proton pump inhibitor | | Rantac | H2 receptor antagonist | | Tagamet | H2 receptor antagonist | | Famocid | H2 receptor antagonist | Why the other options are wrong - Rantac: Ranitidine is an H2 receptor antagonist. - Tagamet: Cimetidine is an H2 receptor antagonist. - Famocid: Famotidine is an H2 receptor antagonist.

  2. 2. What is a feature of short bowel syndrome?

    • A. Malabsorption with diarrhea, anemia and dermatitis herpetiformis
    • B. Maldigestion with steatorrhea, weight loss and hyperglycemia
    • C. Protein loss with edema, hypoalbuminemia and lymphopenia
    • D. Malabsorption with diarrhea, dehydration and malnutrition
    Show answer

    Answer: D. Malabsorption with diarrhea, dehydration and malnutrition

    > Key point: Short bowel syndrome causes malabsorption, leading to diarrhea, dehydration, and malnutrition. Why malabsorption with diarrhea, dehydration and malnutrition is correct - Extensive bowel resection reduces the intestinal surface available to absorb nutrients, water, and electrolytes. - The resulting malabsorption produces diarrhea, dehydration, and malnutrition. How they compare | Pattern | Points to | |---|---| | Malabsorption, diarrhea, dehydration, malnutrition | Short bowel syndrome | | Malabsorption, anemia, dermatitis herpetiformis | Coeliac disease | | Maldigestion, steatorrhea, weight loss, hyperglycemia | Pancreatic disease | | Protein loss, edema, hypoalbuminemia, lymphopenia | Protein-losing enteropathy | Why the other options are wrong - Malabsorption with diarrhea, anemia and dermatitis herpetiformis: dermatitis herpetiformis points to coeliac disease, not loss of bowel length. - Maldigestion with steatorrhea, weight loss and hyperglycemia: this suggests pancreatic digestive and endocrine insufficiency, not reduced intestinal absorptive surface. - Protein loss with edema, hypoalbuminemia and lymphopenia: this suggests protein-losing enteropathy rather than the characteristic nutrient and fluid malabsorption of short bowel syndrome.

  3. 3. Which drug class is NOT typically associated with a clinically significant interaction with warfarin?

    • A. Oral contraceptives
    • B. Barbiturates
    • C. Cephalosporins
    • D. Benzodiazepines
    Show answer

    Answer: D. Benzodiazepines

    > Key point: Benzodiazepines are not typically associated with a clinically significant interaction with warfarin. Why Benzodiazepines is correct - Benzodiazepines generally do not significantly alter warfarin metabolism or its anticoagulant effect. - The other listed classes can affect warfarin response. How they compare | Drug class | Typical interaction with warfarin | |---|---| | Benzodiazepines | No clinically significant interaction typically | | Barbiturates | Can induce metabolism and reduce anticoagulant effect | | Oral contraceptives | Can alter anticoagulant effect | | Cephalosporins | Some can potentiate anticoagulant effect | Why the other options are wrong - Barbiturates: Enzyme induction can increase warfarin metabolism and reduce its effect. - Oral contraceptives: They can alter warfarin’s anticoagulant effect. - Cephalosporins: Some can potentiate anticoagulation and increase bleeding risk.

  4. 4. The following adverse drug reaction seen in colonoscopy view is due to which of the following agents?

    • A. Cascara
    • B. Castor oil
    • C. Bisacodyl
    • D. Loperamide
    Show answer

    Answer: A. Cascara

    > Key point: Chronic cascara use can cause melanosis coli, the characteristic dark pigmentation of the colonic mucosa. Why Cascara is correct - Cascara is an anthraquinone stimulant laxative associated with melanosis coli. - The dark mucosal pigmentation is due to lipofuscin deposits in lamina propria macrophages. Why the other options are wrong - Castor oil: A stimulant laxative, but it is not associated with melanosis coli. - Bisacodyl: A stimulant laxative, but it is not the anthraquinone laxative associated with this pigmentation. - Loperamide: An antidiarrheal that slows intestinal motility, not a cause of melanosis coli.

  5. 5. In adults with acute pancreatitis, which of the following is the most common early systemic complication?

    • A. Circulatory shock
    • B. Arterial hypoxemia
    • C. Disseminated intravascular coagulation
    • D. Acute kidney injury
    Show answer

    Answer: B. Arterial hypoxemia

    > Key point: Arterial hypoxemia is the most common early systemic complication of acute pancreatitis. Why Arterial hypoxemia is correct - It is the most common early systemic complication in adults with acute pancreatitis. - Pancreatic enzymes and inflammatory cytokines can injure the alveolar-capillary membrane and impair oxygenation. Why the other options are wrong - Circulatory shock: It can occur early, particularly in severe disease, but is less common. - Disseminated intravascular coagulation: It may occur in severe disease but is less common. - Acute kidney injury: It can occur early in severe disease but is less common.

  6. 6. Which stool investigation detects occult gastrointestinal blood loss?

    • A. Stool guaiac test
    • B. Faecal calprotectin assay
    • C. Faecal elastase assay
    • D. Stool osmotic gap
    Show answer

    Answer: A. Stool guaiac test

    > Key point: Stool guaiac detects occult blood in stool. Why Stool guaiac test is correct - It detects blood that is not visible in the stool, indicating occult gastrointestinal blood loss. How they compare | Investigation | Main use | |---|---| | Stool guaiac test | Detect occult blood | | Faecal calprotectin assay | Assess intestinal inflammation | | Faecal elastase assay | Assess pancreatic exocrine function | | Stool osmotic gap | Help classify diarrhoea | Why the other options are wrong - Faecal calprotectin assay: assesses intestinal inflammation, not occult blood loss. - Faecal elastase assay: assesses pancreatic exocrine function, not occult blood loss. - Stool osmotic gap: helps classify diarrhoea, not detect blood.

  7. 7. A child develops acute pancreatitis following painful bilateral parotid swelling. Which organism is the most likely cause?

    • A. Coxsackie B virus
    • B. Measles virus
    • C. Mumps virus
    • D. Epstein–Barr virus
    Show answer

    Answer: C. Mumps virus

    > Key point: Mumps classically causes painful bilateral parotitis followed by acute pancreatitis. Why Mumps virus is correct - The painful bilateral parotid swelling is characteristic of mumps. - Pancreatitis can follow mumps parotitis, making this combination the key clue. Clues in the question | Clue | What it points to | |---|---| | “painful bilateral parotid swelling” | Mumps parotitis | | “acute pancreatitis” following the swelling | The classic mumps association | Why the other options are wrong - Coxsackie B virus: Can cause pancreatitis, but does not characteristically cause this parotitis–pancreatitis combination. - Measles virus: Its typical presentation is fever, cough, coryza, conjunctivitis, and rash, not this combination. - Epstein–Barr virus: Parotid swelling can occur, but it is not the classic cause of this syndrome.

  8. 8. Which antibodies are associated with autoimmune hepatitis type IIa?

    • A. p-ANCA antibody
    • B. Antinuclear antibody
    • C. Anti-LKM1 antibody
    • D. Anti-histone antibody
    Show answer

    Answer: C. Anti-LKM1 antibody

    > Key point: Anti-LKM1 antibodies are the characteristic serologic marker of autoimmune hepatitis type IIa. Why Anti-LKM1 antibody is correct - Anti-LKM1 is associated with type IIa autoimmune hepatitis and targets CYP2D6. How they compare | Antibody | Association | |---|---| | Anti-LKM1 | Autoimmune hepatitis type IIa | | p-ANCA | Primary sclerosing cholangitis and ulcerative colitis | | Antinuclear antibody | Autoimmune hepatitis type I | | Anti-histone | Drug-induced lupus erythematosus | Why the other options are wrong - p-ANCA antibody: May occur in autoimmune liver disease, but is more classically associated with primary sclerosing cholangitis and ulcerative colitis. - Antinuclear antibody: More characteristic of autoimmune hepatitis type I. - Anti-histone antibody: Classically associated with drug-induced lupus, not type IIa autoimmune hepatitis.

  9. 9. A 45-year-old man has painless regurgitation of undigested food eaten days earlier, halitosis and intermittent solid-food dysphagia. Examination reveals a left-sided neck swelling that gurgles on palpation. What is the most likely diagnosis?

    • A. Scleroderma
    • B. Achalasia cardia
    • C. Diabetic gastroparesis
    • D. Zenker diverticulum
    Show answer

    Answer: D. Zenker diverticulum

    > Key point: Delayed regurgitation of old food with a gurgling cervical swelling strongly suggests Zenker diverticulum. Why Zenker diverticulum is correct - A pharyngeal pouch can retain food, leading to painless regurgitation of undigested food long after eating and halitosis. - Intermittent solid-food dysphagia and a gurgling left-sided neck swelling are characteristic clues. Clues in the question | Clue | What it points to | |---|---| | “Undigested food eaten days earlier” | Food retained in a pouch | | “Halitosis” and “intermittent solid-food dysphagia” | Retained food and impaired swallowing | | “Left-sided neck swelling that gurgles” | A cervical pharyngeal pouch | Why the other options are wrong - Scleroderma: Esophageal hypomotility and reflux do not explain a gurgling cervical pouch. - Achalasia cardia: Food retention can cause regurgitation, but it does not explain the gurgling neck swelling. - Diabetic gastroparesis: Delayed gastric emptying does not account for the cervical swelling or swallowing symptoms.

  10. 10. Which of the following medications is classified as a stool softener?

    • A. Wheat bran
    • B. Docusate sodium
    • C. Phenolphthalein
    • D. Senna extract
    Show answer

    Answer: B. Docusate sodium

    > Key point: Docusate sodium is classified as a stool softener. Why Docusate sodium is correct - Docusate reduces stool surface tension, allowing water and lipids to enter the stool and soften it. How they compare | Medication | Class or action | |---|---| | Docusate sodium | Stool softener | | Wheat bran | Bulk-forming laxative | | Senna extract | Stimulant laxative | | Phenolphthalein | Stimulant laxative | Why the other options are wrong - Wheat bran: Adds bulk as dietary fiber; it is not classified as a stool softener. - Senna extract: Promotes bowel evacuation as a stimulant laxative. - Phenolphthalein: A stimulant laxative, not a stool softener.

Flashcards: Drugs for Gastrointestinal Diseases

  1. 1. Drug of choice for prevention of NSAID induced peptic ulcer disease is

    Show answer

    Proton Pump Inhibitors (PPIs)

  2. 2. Gastroesophageal reflux _____ receptor antagonists (e.g. cimetidine) may be used to treat _____ and _____, although _____ are the first line treatment

    Show answer

    H2 · GERD · peptic ulcers · PPIs

  3. 3. First Aid Pharmacology: GI_____ is a combination drug that may be used to treat _____ and _____

    Show answer

    Sulfasalazine · ulcerative colitis · Crohn disease (colitis component)

  4. 4. _____ is a gastroprokinetic agent which acts as a _____ receptor agonist

    Show answer

    Cisapride · 5-HT4

  5. 5. Vedolizumab is an anti- monoclonal antibody that is used in the treatment of Crohn's disease and Ulcerative Colitis

    Show answer

    α4β7 integrin (alpha-4 beta-7 integrin)

  6. 6. Bile acid resins can lead to _____, which may impair the absorption of _____

    Show answer

    steatorrhea · fat-soluble vitamins (A, D, E, K)

  7. 7. _____ is _____ receptor antagonist used in treatment of _____

    Show answer

    Netazepide · CCK-B · gastrinoma/Zollinger-Ellison Syndrome

  8. 8. Because PGE1 is involved in physiological responses of the gut mucosa and the uterine smooth muscle, Misoprostol can cause _____ as well as uterine _____

    Show answer

    diarrhea · contractions

  9. 9. _____ (macrolide) can bind GI _____, increasing GI motility and causing diarrhea

    Show answer

    Erythromycin · motilin receptors

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF